Logo image of IXHL

INCANNEX HEALTHCARE INC (IXHL) Stock Fundamental Analysis

NASDAQ:IXHL - Nasdaq - US45333F1093 - Common Stock - Currency: USD

0.1265  -0.01 (-4.82%)

Fundamental Rating

2

IXHL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. IXHL may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, IXHL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IXHL had negative earnings in the past year.
In the past year IXHL has reported a negative cash flow from operations.
IXHL had negative earnings in each of the past 5 years.
IXHL had a negative operating cash flow in each of the past 5 years.
IXHL Yearly Net Income VS EBIT VS OCF VS FCFIXHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

With a Return On Assets value of -214.35%, IXHL is not doing good in the industry: 88.89% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -2466.94%, IXHL is doing worse than 83.33% of the companies in the same industry.
Industry RankSector Rank
ROA -214.35%
ROE -2466.94%
ROIC N/A
ROA(3y)-117.62%
ROA(5y)-108.95%
ROE(3y)-146.83%
ROE(5y)-135.42%
ROIC(3y)N/A
ROIC(5y)N/A
IXHL Yearly ROA, ROE, ROICIXHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K

1.3 Margins

IXHL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IXHL Yearly Profit, Operating, Gross MarginsIXHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K -250K

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for IXHL remains at a similar level compared to 1 year ago.
The number of shares outstanding for IXHL has been reduced compared to 5 years ago.
IXHL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IXHL Yearly Shares OutstandingIXHL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
IXHL Yearly Total Debt VS Total AssetsIXHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

IXHL has an Altman-Z score of -23.09. This is a bad value and indicates that IXHL is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -23.09, IXHL is not doing good in the industry: 84.85% of the companies in the same industry are doing better.
A Debt/Equity ratio of 3.90 is on the high side and indicates that IXHL has dependencies on debt financing.
IXHL has a Debt to Equity ratio of 3.90. This is amonst the worse of the industry: IXHL underperforms 81.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.9
Debt/FCF N/A
Altman-Z -23.09
ROIC/WACCN/A
WACCN/A
IXHL Yearly LT Debt VS Equity VS FCFIXHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 1.80 indicates that IXHL should not have too much problems paying its short term obligations.
IXHL has a Current ratio of 1.80. This is in the lower half of the industry: IXHL underperforms 62.63% of its industry peers.
IXHL has a Quick Ratio of 1.80. This is a normal value and indicates that IXHL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.80, IXHL is in line with its industry, outperforming 41.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.8
Quick Ratio 1.8
IXHL Yearly Current Assets VS Current LiabilitesIXHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.01% over the past year.
The Revenue has been growing by 49.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)64.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.27%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-79.08%
Revenue growth 5Y49.63%
Sales Q2Q%N/A

3.2 Future

IXHL is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -63.44% yearly.
IXHL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 707.99% yearly.
EPS Next Y-116.51%
EPS Next 2Y-63.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3817.05%
Revenue Next 2Y707.99%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IXHL Yearly Revenue VS EstimatesIXHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 200K 400K 600K 800K 1M
IXHL Yearly EPS VS EstimatesIXHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IXHL. In the last year negative earnings were reported.
Also next year IXHL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IXHL Price Earnings VS Forward Price EarningsIXHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IXHL Per share dataIXHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

IXHL's earnings are expected to decrease with -63.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.44%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IXHL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INCANNEX HEALTHCARE INC

NASDAQ:IXHL (5/2/2025, 1:06:02 PM)

0.1265

-0.01 (-4.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-14 2025-02-14/bmo
Earnings (Next)N/A N/A
Inst Owners3.7%
Inst Owner Change0%
Ins Owners25.55%
Ins Owner Change0%
Market Cap3.49M
AnalystsN/A
Price TargetN/A
Short Float %1.02%
Short Ratio1.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1321.88%
Min EPS beat(2)-1352.83%
Max EPS beat(2)-1290.92%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.91%
EPS NY rev (1m)0%
EPS NY rev (3m)1.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 35.56
P/FCF N/A
P/OCF N/A
P/B 3.61
P/tB 3.61
EV/EBITDA N/A
EPS(TTM)-1.4
EYN/A
EPS(NY)-3.05
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -214.35%
ROE -2466.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-117.62%
ROA(5y)-108.95%
ROE(3y)-146.83%
ROE(5y)-135.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 3.9
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 5.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.8
Quick Ratio 1.8
Altman-Z -23.09
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.27%
EPS Next Y-116.51%
EPS Next 2Y-63.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-79.08%
Revenue growth 5Y49.63%
Sales Q2Q%N/A
Revenue Next Year3817.05%
Revenue Next 2Y707.99%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-109.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.64%
OCF growth 3YN/A
OCF growth 5YN/A